
    sponsor
  
['motor neuron disease']
['flx-787-odt (orally disintegrating tablet)', 'placebo odt']

        Inclusion Criteria:

          -  Documented diagnosis of Motor Neuron Disease (MND) [including Amyotrophic Lateral
             Sclerosis (ALS), Primary Lateral Sclerosis (PLS) or Progressive Muscular Atrophy
             (PMA)]

          -  Expected survival > 6 months

          -  Weekly muscle cramping (defined as: a sustained muscle contraction that's most often
             painful and lasts seconds to minutes)

        Exclusion Criteria:

          -  Presence of major gastrointestinal disorders, such as inflammatory bowel disease,
             diverticulitis, active peptic ulcer disease, or significant gastroesophageal reflux
             disease (i.e., not well-controlled on antacids or proton pump inhibitors), or oral or
             esophageal lesions/ulcers

          -  Presence of laryngospasm or significant swallowing problems

          -  Presence of percutaneous endoscopic gastrostomy, esophagogastroduodenoscopy, or G-tube

          -  Unable or unwilling to discontinue medications for cramps and/or opiates

          -  Inability to tolerate a spicy sensation in the mouth or stomach

          -  Actively using illicit drugs or history of chronic substance abuse within the past
             year prior to screening, including abuse of alcohol

          -  Intention to change the current level of tobacco use or use of nicotine-containing
             products (i.e., new smokers or those actively trying to quit may not enrolled)

          -  Participated in a clinical study (except natural history studies without
             administration of an investigational product) within 30 days prior to screening
      